LinusBio is developing a platform to identify precision exposome biomarkers for such conditions as pediatric cancer, inflammatory bowel disease, psychosis, schizophrenia, and amyotrophic lateral sclerosis, or ALS.
“Our mission is simple: to deliver better outcomes for people and families affected by complex health conditions,” said Manish Arora, PhD, co-founder and CEO of LinusBio and professor at Icahn School of Medicine at Mount Sinai, in a Jan. 12 news release. “We chose to focus on autism first for many considerations, an important one of them is the dramatically different trajectory in cases of an early detection and effective intervention.”
LinusBio, which was developed with Mount Sinai Innovation Partners, said one of its early technologies can predict the likelihood of autism at birth with 80 percent to 90 percent accuracy.
The funding round was led by GreatPoint Ventures and Bow Capital.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
